Key result
Suloctidil plus antivitamin K increases platelet survival and reduces platelet retention vs. antivitamin K alone.
Why the study?
The effects of suloctidil on platelet survival time after cardiac valve replacement in patients with shortened platelet survival were unclear.
Does suloctidil added to antivitamin K improve platelet survival time in patients with shortened platelet survival after cardiac valve replacement?
RCT (n=23)
Randomized
Does suloctidil added to antivitamin K improve platelet survival time in patients with shortened platelet survival after cardiac valve replacement?
Suloctidil added to antivitamin K significantly improves platelet survival time and reduces platelet destruction in patients after cardiac valve replacement.
Answers are grounded in this paper and cite their sources.
Supports adjunctive suloctidil post-valve replacement; confirms platelet kinetic benefit in RCT.
Platelet functions and blood clotting parameters were examined in 23 patients with a shortened platelet survival time after cardiac valve replacement. Treatment was given at random: for a first group antivitamin K with suloctidil and for the second group antivitamin K alone. Six weeks of treatment with antivitamin K alone did not induce any significant change in the platelet survival time, platelet retention or platelet factor 4 in plasma. In contrast, the shortened platelet survival time increased significantly after 6 weeks of treatment with suloctidil. Moreover the platelet retention and the amount of platelet factor 4 in plasma were significantly reduced, indicating that normalization of platelet survival is the result of decreased destruction, presumably at the level of the prosthetic surface. The clinical benefits expected from these results remain to be validated by a longer follow up period.
No takes yet. Share an insight, caveat, or question.
Beys et al. (1981) conducted an RCT in Shortened platelet survival time after cardiac valve replacement (n=23). Suloctidil with antivitamin K vs. Antivitamin K alone was evaluated on Platelet survival time, platelet retention, and platelet factor 4 in plasma. Suloctidil combined with antivitamin K significantly increased platelet survival time and reduced platelet retention and platelet factor 4 compared to antivitamin K alone over 6 weeks.
Synapse has enriched 10 related papers. Consider them for comparative context: